Study of Didox, a Ribonucleotide Reductase Inhibitor
Author Information
Author(s): D. Veale, S. B. Kaye, J. Carmichael, B.M.J. Cantwell, H.L. Elford, R. Blackie, D.J. Kerr, A.L. Harris
Primary Institution: University Department of Clinical Oncology, Newcastle General Hospital
Hypothesis
Can didox be safely administered to patients with unresponsive metastatic carcinoma?
Conclusion
Didox can be safely given by slow intravenous injection at a dose of 6 gm-2, but no clinical responses were observed in the study.
Supporting Evidence
- Didox was administered to 34 patients with unresponsive metastatic carcinoma.
- Peak levels of didox were achieved within 5 minutes of injection.
- Minor toxicity was noted at lower doses, but severe toxicity was observed at higher doses.
Takeaway
Didox is a new drug that was tested on cancer patients, but it didn't help them get better, even though it was safe to use.
Methodology
Patients with metastatic carcinoma received escalating doses of didox via slow intravenous injection, and pharmacokinetic studies were conducted.
Limitations
No clinical responses were observed, and the study involved patients with generally unresponsive tumor types.
Participant Demographics
Mean age of participants was 56 years, with 23 males and 11 females.
Want to read the original?
Access the complete publication on the publisher's website